Skip to content

Efficacy and safety of indoor air purification in the treatment of artemisia pollen allergic rhinitis: study protocol for a randomized controlled trial

Efficacy and safety of indoor air purification in the treatment of artemisia pollen allergic rhinitis: study protocol for a randomized controlled trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-17012481
Enrollment
Unknown
Registered
2017-08-26
Start date
2016-06-01
Completion date
Unknown
Last updated
2017-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

allergic rhinitis

Interventions

active air cleaner:active air cleaner treatment
Control:placebo air cleaner

Sponsors

Yulin First Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) with confirmed allergic rhinitis; (2) the patients are sensitive to artemisia pollen allergens; (3) aged 18 to 65 years; (4) informed consent and volunteer to participate the study; (5) to complete the CRF and other records.

Exclusion criteria

Exclusion criteria: (1) psychopath; (2) the patients have systemic disease which the researchers consider unsuitable for the study; (3) not cooperated with the examination; (4) work places changed from time to time which would be lost to follow up possibly; (5) the patients have dysgnosia or behavior disorder; (6) the patients has any diseases as following: nasal polyp, chronic sinusitis, severe nasal diviation, medicamentous rhinitis, primary sleep disorders for more than one night a week, obstructive sleep apnea syndrome, upper respiratory infection within 2 weeks before enrollment, poorly controlled asthma; (7) women who are pregnant, or may possibly become pregnant, or who are lactating with a positive urine pregnant test; (8) history of drug abuse within three years; (9) necessity to sleep in a different bed more than six times in 3 weeks or more than 3 consecutive nights; (10)history of smoking within one year; (11) the patients are sensitive to indoor allergens, such as dust mite, pet dander, et al.; (12) Other reasons at the investigators discretion.

Design outcomes

Primary

MeasureTime frame
The Visual Analog Scale (VAS);

Secondary

MeasureTime frame
the change in nasal signs;allergy symptom score;the Rhinoconjunctivitis Quality of Life Questionnaire(RQLQ);Epworth Sleepiness Scale score;

Countries

China

Contacts

Public ContactLi Li

Yulin First Hospital

1587074266@qq.com+86 18992273362

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 6, 2026